Ding et al., 2024 - Google Patents
Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonistsDing et al., 2024
- Document ID
- 6250076634682026886
- Author
- Ding D
- Gao R
- Lei Y
- Liu J
- Zhou C
- Wen Y
- Zhou S
- Guo J
- Li T
- Publication year
- Publication venue
- European Journal of Medicinal Chemistry
External Links
Snippet
Enhancing the efficacy of subunit vaccines relies significantly on the utilization of potent adjuvants, particularly those capable of triggering multiple immune pathways. To achieve synergistic immune augmentation by Toll-like receptor 4 agonist (TLR4a) and nucleotide …
- 102100039360 Toll-like receptor 4 0 title abstract description 54
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ding et al. | Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists | |
| Diwan et al. | Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres | |
| Diwan et al. | Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery | |
| AU2009241645B2 (en) | Products and methods for stimulating an immune response | |
| KR102374576B1 (en) | Thermostable vaccine compositions and methods of preparing same | |
| Correia-Neves et al. | Lipoarabinomannan in active and passive protection against tuberculosis | |
| Gray et al. | Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant | |
| Huang et al. | Potent antigen-adjuvant delivery system by conjugation of Mycobacterium tuberculosis Ag85B-HspX fusion protein with arabinogalactan-Poly (I: C) conjugate | |
| EP2484375A3 (en) | Vaccine composition containing synthetic adjuvant | |
| CZ20031299A3 (en) | Compound vaccine | |
| Zhou et al. | Alum adjuvant and built-in TLR7 agonist synergistically enhance anti-MUC1 immune responses for cancer vaccine | |
| Deepe Jr et al. | Vaccination with an alkaline extract of Histoplasma capsulatum packaged in glucan particles confers protective immunity in mice | |
| Liu et al. | Polysaccharide PCP-I isolated from Poria cocos enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine | |
| Gartlan et al. | Sterile inflammation induced by Carbopol elicits robust adaptive immune responses in the absence of pathogen-associated molecular patterns | |
| Bolhassani et al. | Endogenous and exogenous natural adjuvants for vaccine development | |
| Krieg | CpG DNA: trigger of sepsis, mediator of protection, or both? | |
| Nguyen et al. | Th1/Th17 T cell tissue-resident immunity increases protection, but is not required in a vaccine strategy against genital infection with Chlamydia trachomatis | |
| Weilhammer et al. | Enhancement of antigen-specific CD4+ and CD8+ T cell responses using a self-assembled biologic nanolipoprotein particle vaccine | |
| Sun et al. | Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons | |
| de Velasco et al. | Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines | |
| Cerundolo et al. | Synthetic iNKT cell-agonists as vaccine adjuvants—finding the balance | |
| Chang et al. | Conjugation of PEG-hexadecane markedly increases the immunogenicity of pneumococcal polysaccharide conjugate vaccine | |
| Hayashi et al. | Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2 | |
| Sun et al. | Conjugation reaction with 8-arm PEG markedly improves the immunogenicity of Mycobacterium tuberculosis CFP10-TB10. 4 fusion protein | |
| Sarkar et al. | Residue-specific protein-glycan conjugation strategies for the development of pharmaceutically promising glycoconjugate vaccines: A recent update |